Groupe la Francaise’s NovoCure NVCR Stock Holding History

Groupe la Francaise’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-420	Closed	-$4.62K	–	671
2025 Q3	$4.62K	Buy	+420	New	+$5.61K	﹤0.01%	646

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Groupe la Francaise's NVCR Position: Q4 2025 in Review

Groupe la Francaise sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 420 shares — an estimated $4.62K sold.

Groupe la Francaise first reported a position in NVCR in Q3 2025 and held it in 1 quarter. The position peaked at $4.62K in Q3 2025. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

Groupe la Francaise reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
Groupe la Francaise sold 420 NovoCure shares in Q4 2025, an estimated $4.62K.
Groupe la Francaise first reported a position in NovoCure in Q3 2025 and held it in 1 quarter.
Groupe la Francaise's NovoCure position peaked at $4.62K in Q3 2025.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Groupe la Francaise's 13F filing for Q4 2025, filed 12 Feb 2026.